HRP20211336T1 - Difluorometil-aminopiridini i difluorometil-aminopirimidini - Google Patents

Difluorometil-aminopiridini i difluorometil-aminopirimidini Download PDF

Info

Publication number
HRP20211336T1
HRP20211336T1 HRP20211336TT HRP20211336T HRP20211336T1 HR P20211336 T1 HRP20211336 T1 HR P20211336T1 HR P20211336T T HRP20211336T T HR P20211336TT HR P20211336 T HRP20211336 T HR P20211336T HR P20211336 T1 HRP20211336 T1 HR P20211336T1
Authority
HR
Croatia
Prior art keywords
difluoromethyl
amine
triazin
pyridin
azabicyclo
Prior art date
Application number
HRP20211336TT
Other languages
English (en)
Inventor
Vladimir Cmiljanovic
Paul Hebeisen
Florent Beaufils
Thomas Bohnhacker
Denise RAGEOT
Alexander SELE
Matthias Wymann
Jean-baptiste LANGLOIS
Original Assignee
Torqur Ag
Universität Basel Vizerektorat Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torqur Ag, Universität Basel Vizerektorat Forschung filed Critical Torqur Ag
Publication of HRP20211336T1 publication Critical patent/HRP20211336T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (15)

1. Spoj formule (I), [image] gdje X1, X2 i X3, neovisno jedan o drugome, su N ili CH; pod uvjetom da su najmanje dva od X1, X2 i X3 N; Y je N ili CH; R1 i R2 su neovisno jedno o drugome (i) morfolinil formule (II) [image] gdje strelica označava vezu u formuli (I); i gdje su R3 i R4, neovisno jedan o drugome, H, C1-C3alkil po izboru supstituiran s jednim ili dva od OH, C1-C2fluoroalkil, C1-C2alkoksi, C1-C2alkoksiC1-C3alkil, CN ili C(O)O-C1-C2alkil; ili R3 i R4 zajedno oblikuju dvovalentni ostatak -R5R6- odabran iz -CH2-O-CH2-, -CH2-NH-CH2- ili C1‑C3alkilena izborno supstituiranog s od 1 do 4 F, ili bilo koju od struktura [image] gdje strelice označavaju veze u formuli (II); ili (ii) zasićeni 5- do 6-člani heterociklički prsten Z koji sadrži 1 do 2 heteroatoma neovisno odabrana od N, O i S, po izboru supstituiran s od 1 do 3 R9; pri čemu je R9, nezavisno pri svakom pojavljivanju, halogen, -OH, C1-C3alkil, CH2OH, CH2CH2OH, CH2F, CHF2, CF3, CH2CF3, C1-C2alkoksi, C1-C2alkoksiC1-C3alkil, C3-C6cikloalkil, =O, -NH2, NHCH3 ili N(CH3)2; ili dva R9 supstituenta zajedno oblikuju dvovalentni ostatak -R10R11- odabran od -CH2-O-CH2-, -O-CH2CH2-O- ili C1-C3alkilena izborno supstituiranog s od 1 do 4 F; pod uvjetom da je najmanje jedan od R1 i R2 morfolinil formule II; i njegovi tautomeri, solvati i farmaceutski prihvatljive soli.
2. Spoj formule (I) sukladno patentnom zahtjevu 1, gdje su X1, X2 i X3 N; i njegovi tautomeri, solvati i farmaceutski prihvatljive soli.
3. Spoj formule (I) sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, gdje su navedeni R1 i navedeni R2,neovisno jedan o drugome, odabrani iz [image] [image] [image] [image] [image] [image] [image] [image] [image] [image]
4. Spoj formule (I) sukladno patentnom zahtjevu 3, gdje su R1 i R2 neovisno jedan o drugome, odabrani iz [image] [image]
5. Spoj formule (I) sukladno patentnom zahtjevu 1, pri čemu je navedeni spoj odabran iz 4-(difluorometil)-5-(4,6-dimorfolino-1,3,5-triazin-2-il)piridin-2-amina; 4-(difluorometil)-5-(4,6-dimorfolino-1,3,5-triazin-2-il)pirimidin-2-amina; 5-(4-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-6-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-1,3,5-triazin-2-il)-4-(difluorometil)piridin-2-amina; 5-(4-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-6-morfolino-1,3,5-triazin-2-il)-4-(difluorometil)piridin-2-amina; 5-(4-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-6-morfolino-1,3,5-triazin-2-il)-4-(difluorometil)pirimidin-2-amina; 5-(4,6-bis((S)-3-metilmorfolino)-1,3,5-triazin-2-il)-4-(difluorometil)piridin-2-amina; 5-(4,6-bis((S)-3-metilmorfolino)-1,3,5-triazin-2-il)-4-(difluorometil)pirimidin-2-amina; (S)-4-(difluorometil)-5-(4-(3-metilmorfolino)-6-morfolino-1,3,5-triazin-2-il)piridin-2-amina; (S)-4-(difluorometil)-5-(4-(3-metilmorfolino)-6-morfolino-1,3,5-triazin-2-il)pirimidin-2-amina; 5-(4-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-6-((S)-3-metilmorfolino)-1,3,5-triazin-2-il)-4-(difluorometil)piridin-2-amina; 5-(4-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-6-((S)-3-metilmorfolino)-1,3,5-triazin-2-il)-4-(difluorometil)pirimidin-2-amina; 4-(difluorometil)-5-(4-morfolino-6-(piperazin-1-il)-1,3,5-triazin-2-il)piridin-2-amina; 4-(difluorometil)-5-(4-morfolino-6-(piperazin-1-il)-1,3,5-triazin-2-il)pirimidin-2-amina; (S)-4-(difluorometil)-5-(4-(3-metilmorfolino)-6-(piperazin-1-il)-1,3,5-triazin-2-il)piridin-2-amina; (S)-4-(difluorometil)-5-(4-(3-metilmorfolino)-6-(piperazin-1-il)-1,3,5-triazin-2-il)pirimidin-2-amina; 4-(difluorometil)-5-(2,6-dimorfolinopirimidin-4-il)piridin-2-amina; 4'-(difluorometil)-2,6-dimorfolino-[4,5'-bipirimidin]-2'-amina; 4-(difluorometil)-5-(4,6-dimorfolinopirimidin-2-il)piridin-2-amina; 4'-(difluorometil)-4,6-dimorfolino-[2,5'-bipirimidin]-2'-amina; 4-(difluorometil)-5-(4-morfolino-6-tiomorfolino-1,3,5-triazin-2-il)piridin-2-amina; 4-(difluorometil)-5-(4-morfolino-6-tiomorfolino-1,3,5-triazin-2-il)pirimidin-2-amina; 5-(6-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-2-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)pirimidin-4-il)-4-(difluorometil)piridin-2-amina; 5-(2-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-6-morfolinopirimidin-4-il)-4-(difluorometil)piridin-2-amina; 2-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-4'-(difluorometil)-6-morfolino-[4,5'-bipirimidin]-2'-amina; 5-(2,6-bis((S)-3-metilmorfolino)pirimidin-4-il)-4-(difluorometil)piridin-2-amina; 4'-(difluorometil)-2,6-bis((S)-3-metilmorfolino)-[4,5'-bipirimidin]-2'-amina; (S)-4-(difluorometil)-5-(6-(3-metilmorfolino)-2-morfolinopirimidin-4-il)piridin-2-amina; (S)-4’-(difluorometil)-6-(3-metilmorfolino)-2-morfolino-[4,5'-bipirimidin]-2'-amina; 5-(4-(8-oksa-3-azabiciklo[3.2.1]oktan-3-il)-6-(8-oksa-3-azabiciklo[3.2.1]oktan-3-il)-1,3,5-triazin-2-il)-4-(difluorometil)piridin-2-amina; 5-[4,6-bis(2,2-dimetilmorfolin-4-il)-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; (S)-4-(difluorometil)-5-(2-(3-metilmorfolino)-6-morfolinopirimidin-4-il)piridin-2-amina; (S)-4’-(difluorometil)-2-(3-metilmorfolino)-6-morfolino-[4,5'-bipirimidin]-2'-amina; 4-(difluorometil)-5-[4-[(2S,6R)-2,6-dimetilmorfolin-4-il]-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 5-[4,6-bis[(2R,6S)-2,6-dimetilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 4-[4-[6-amino-4-(difluorometil)-3-piridil]-6-morfolino-1,3,5-triazin-2-il]morfolin-3-ona; 4-[4-[2-amino-4-(difluorometil)pirimidin-5-il]-6-morfolino-1,3,5-triazin-2-il]morfolin-3-ona; 5-[4,6-bis(3,7-dioksa-9-azabiciklo[3.3.1]nonan-9-il)-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 4-(difluorometil)-5-[4-(3,7-dioksa-9-azabiciklo[3.3.1]nonan-9-il)-6-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-1,3,5-triazin-2-il]piridin-2-amina; 5-[4,6-bis(3,3-dimetilmorfolin-4-il)-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 5-[4,6-bis[(3R,5S)-3,5-dimetilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 5-[4,6-bis[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 4-(difluorometil)-5-[4-(3,3-dimetilmorfolin-4-il)-6-morfolino-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3R,5S)-3,5-dimetilmorfolin-4-il]-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-(3,3-dimetilmorfolin-4-il)-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3R)-3-(metoksimetil)morfolin-4-il]-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-(3,7-dioksa-9-azabiciklo[3.3.1]nonan-9-il)-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; (4S,5R)-3-[4-[2-amino-4-(difluorometil)pirimidin-5-il]-6-morfolino-1,3,5-triazin-2-il]-4-(hidroksimetil)-5-metil-oksazolidin-2-ona; (4S,5R)-3-[6-[2-amino-4-(difluorometil)pirimidin-5-il]-2-morfolino-pirimidin-4-il]-4-(hidroksimetil)-5-metil-oksazolidin-2-ona; 4-(difluorometil)-5-[4-[(3R)-3-metilmorfolin-4-il]-6-(3-oksa-6-azabiciklo[3.1.1]heptan-6-il)-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3R)-3-metilmorfolin-4-il]-6-(6-oksa-3-azabiciklo[3.1.1]heptan-3-il)-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3R)-3-metilmorfolin-4-il]-6-[(1R,4R)-2-oksa-5-azabiciklo[2.2.1]heptan-5-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3R)-3-metilmorfolin-4-il]-6-[(1S,4S)-2-oksa-5-azabiciklo[2.2.1]heptan-5-il]-1,3,5-triazin-2-il]piridin-2-amina; 5-[4,6-bis[(3R)-3-etilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 5-[4,6-bis(8-oksa-5-azaspiro[3,5]nonan-5-il)-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 5-[4,6-bis[(3R)-3-izopropilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 5-[4-[(3aR,6aS)-1,3,3a,4,6,6a-heksahidrofuro[3,4-c]pirol-5-il]-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 5-[4-[(4aS,7aR)-2,3,4a,5,7,7a-heksahidro-[1,4]dioksino[2,3-c]pirol-6-il]-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 4-(difluorometil)-5-[4-(4,4-difluoro-1-piperidil)-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3R)-3-metilmorfolin-4-il]-6-(2-oksa-7-azaspiro[3.5]nonan-7-il)-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-(3,3-dimetilmorfolin-4-il)-6-[(3R,5S)-3,5-dimetilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-(3,3-dimetilmorfolin-4-il)-6-[(3R)-3-(metoksimetil)morfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; [(3R)-4-[4-[6-amino-4-(difluorometil)-3-piridil]-6-(3,3-dimetilmorfolin-4-il)-1,3,5-triazin-2-il]morfolin-3-il]metanola; 4-(difluorometil)-5-[4-(3,3-dimetilmorfolin-4-il)-6-(3,7-dioksa-9-azabiciklo[3.3.1]nonan-9-il)-1,3,5-triazin-2-il]piridin-2-amina; 5-[4-(4-ciklopropilpiperazin-1-il)-6-(3,3-dimetilmorfolin-4-il)-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 4-(difluorometil)-5-[4-(3,3-dimetilmorfolin-4-il)-6-[4-(2-metoksietil)piperazin-1-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-(3,3-dimetilmorfolin-4-il)-6-(1,1-diokso-1,4-tiazinan-4-il)-1,3,5-triazin-2-il]piridin-2-amina; [(3R)-4-[4-[6-amino-4-(difluorometil)-3-piridil]-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]morfolin-3-il]metanola; 4-(difluorometil)-5-[4-[(3R,5R)-3,5-dimetilmorfolin-4-il]-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3S,5S)-3,5-dimetilmorfolin-4-il]-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-morfolino-6-(3-oksa-9-azabiciklo[3.3.1]nonan-9-il)-1,3,5-triazin-2-il]piridin-2-amina; 5-[4,6-bis(3-oksa-9-azabiciklo[3.3.1]nonan-9-il)-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 5-[4-[6-amino-4-(difluorometil)-3-piridil]-6-(3,7-dioksa-9-azabiciklo[3.3.1]nonan-9-il)-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 4-(difluorometil)-5-[4-[(3R)-3-metilmorfolin-4-il]-6-(4-morfolino-1-piperidil)-1,3,5-triazin-2-il]piridin-2-amina; 5-[4-(4-ciklopropilpiperazin-1-il)-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 5-[4-(4-ciklopropilpiperazin-1-il)-6-[(3S,5R)-3,5-dimetilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 4-(difluorometil)-5-[4-[4-(2-metoksietil)piperazin-1-il]-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3S,5R)-3,5-dimetilmorfolin-4-il]-6-[4-(2-metoksietil)piperazin-1-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-(1,1-diokso-1,4-tiazinan-4-il)-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3S,5R)-3,5-dimetilmorfolin-4-il]-6-(1,1-diokso-1,4-tiazinan-4-il)-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3R,5S)-3,5-dimetilmorfolin-4-il]-6-(3,7-dioksa-9-azabiciklo[3.3.1]nonan-9-il)-1,3,5-triazin-2-il]piridin-2-amina; 3-[4-[6-amino-4-(difluorometil)-3-piridil]-6-[(3R,5S)-3,5-dimetilmorfolin-4-il]-1,3,5-triazin-2-il]oksazolidin-2-ona; 5-(4-((1R,2R,4S,5S)-7-oksa-9-azatriciklo[3.3.1.02,4]nonan-9-il)-6-((2R,4S)-7-oksa-9-azatriciklo[3.3.1.02,4]nonan-9-il)-1,3,5-triazin-2-il)-4-(difluorometil)piridin-2-amina; 5-[4,6-bis(6,6-difluoro-3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 5-[4,6-bis(6,7-difluoro-3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-1,3,5-triazin-2-il]-4-(difluorometil))piridin-2-amina; 5-[4-(6-amino-3-piridil)-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina
6. Spoj formule (I) sukladno patentnom zahtjevu 5, pri čemu je navedeni spoj odabran iz skupine koju čine - 4-(difluorometil)-5-(4,6-dimorfolino-1,3,5-triazin-2-il)pirimidin-2-amin; - 5-(4-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-6-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-1,3,5-triazin-2-il)-4-(difluorometil)piridin-2-amin; - 5-(4-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-6-morfolino-1,3,5-triazin-2-il)-4-(difluorometil)piridin-2-amin; - 5-(4,6-bis((S)-3-metilmorfolino)-1,3,5-triazin-2-il)-4-(difluorometil)pirimidin-2-amin; - (S)-4-(difluorometil)-5-(4-(3-metilmorfolino)-6-morfolino-1,3,5-triazin-2-il)piridin-2-amin; - 4-(difluorometil)-5-(4-morfolino-6-(piperazin-1-il)-1,3,5-triazin-2-il)pirimidin-2-amin; - 4-(difluorometil)-5-(4,6-dimorfolino-1,3,5-triazin-2-il)piridin-2-amin; i - (S)-4-(difluorometil)-5-(4-(3-metilmorfolino)-6-morfolino-1,3,5-triazin-2-il)pirimidin-2-amin; i njihovi tautomeri, solvati i farmaceutski prihvatljive soli
7. Spoj formule (I) sukladno patentnom zahtjevu 6, pri čemu je navedeno Spoj odabrano od, - 4-(difluorometil)-5-(4,6-dimorfolino-1,3,5-triazin-2-il)pirimidin-2-amina; - 5-(4-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-6-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-1,3,5-triazin-2-il)-4-(difluorometil)piridin-2-amina; - (S)-4-(difluorometil)-5-(4-(3-metilmorfolino)-6-morfolino-1,3,5-triazin-2-il)piridin-2-amina; i njihovih tautomera, solvata i farmaceutski prihvatljivih soli.
8. Spoj formule (I) sukladno patentnom zahtjevu 5, pri čemu je navedeni spoj odabran iz 4-[4-[6-amino-4-(difluorometil)-3-piridil]-6-morfolino-1,3,5-triazin-2-il]morfolin-3-ona; 4-[4-[2-amino-4-(difluorometil)pirimidin-5-il]-6-morfolino-1,3,5-triazin-2-il]morfolin-3-ona; 5-[4,6-bis(3,7-dioksa-9-azabiciklo[3.3.1]nonan-9-il)-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 4-(difluorometil)-5-[4-(3,7-dioksa-9-azabiciklo[3.3.1]nonan-9-il)-6-(3-oksa-8-azabiciklo[3.2.1]oktan-8-il)-1,3,5-triazin-2-il]piridin-2-amina; 5-[4,6-bis(3,3-dimetilmorfolin-4-il)-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 5-[4,6-bis[(3R,5S)-3,5-dimetilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 5-[4,6-bis[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]-4-(difluorometil)piridin-2-amina; 4-(difluorometil)-5-[4-(3,3-dimetilmorfolin-4-il)-6-morfolino-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3R,5S)-3,5-dimetilmorfolin-4-il]-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-(3,3-dimetilmorfolin-4-il)-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-[(3R)-3-(metoksimetil)morfolin-4-il]-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; 4-(difluorometil)-5-[4-(3,7-dioksa-9-azabiciklo[3.3.1]nonan-9-il)-6-[(3R)-3-metilmorfolin-4-il]-1,3,5-triazin-2-il]piridin-2-amina; (4S,5R)-3-[4-[2-amino-4-(difluorometil)pirimidin-5-il]-6-morfolino-1,3,5-triazin-2-il]-4-(hidroksimetil)-5-metil-oksazolidin-2-ona;
9. Spoj formule (I) sukladno bilo kojem od patentnih zahtjeva od 1 do 4, gdje su R1 i R2, nezavisno jedan o drugome, morfolinil formule (II).
10. Spoj formule (I) sukladno patentnom zahtjevu 9, gdje je R1 jednak R2.
11. Spoj formule (I) sukladno patentnom zahtjevu 9, gdje R1 nije jednak R2.
12. Spoj formule (I) sukladno bilo kom od patentnih zahtjeva od 1 do 4, gdje su R1 i R2, nezavisno jedan o drugome, morfolinil formule (II) i navedeni zasićeni 5- do 6-člani heterocikličku prsten Z.
13. Spoj formule (I) sukladno patentnom zahtjevu 12, gdje je navedeni 5- do 6-člani heterociklički prsten Z odabran od [image]
14. Farmaceutski pripravak koji sadrži spoj formule (I) sukladno bilo kojem od patentnih zahtjeva od 1 do 13 i farmaceutski prihvatljiv nosač.
15. Spoj formule (I) sukladno bilo kojem od patentnih zahtjeva od 1 do 13 za uporabu u postupku prevencije ili liječenja bolesti ili poremećaja moduliranog s PI3K i/ili mTOR i/ili PIKK, koji obuhvaća primjenu učinkovite količine navedenog spoja formule (I) sisavcu kojem je takva prevencija ili liječenje potrebno, pri čemu je navedena bolest ili poremećaj hiperproliferativni poremećaj.
HRP20211336TT 2014-11-11 2021-08-19 Difluorometil-aminopiridini i difluorometil-aminopirimidini HRP20211336T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192617 2014-11-11
EP15791315.3A EP3218358B1 (en) 2014-11-11 2015-11-10 Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
PCT/EP2015/076192 WO2016075130A1 (en) 2014-11-11 2015-11-10 Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines

Publications (1)

Publication Number Publication Date
HRP20211336T1 true HRP20211336T1 (hr) 2021-11-26

Family

ID=51868133

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211336TT HRP20211336T1 (hr) 2014-11-11 2021-08-19 Difluorometil-aminopiridini i difluorometil-aminopirimidini

Country Status (23)

Country Link
US (3) US10640516B2 (hr)
EP (1) EP3218358B1 (hr)
JP (1) JP6689843B2 (hr)
KR (1) KR20170101899A (hr)
CN (1) CN107108644B (hr)
AU (1) AU2015345233B2 (hr)
CA (1) CA2965565C (hr)
CY (1) CY1124444T1 (hr)
DK (1) DK3218358T3 (hr)
ES (1) ES2886008T3 (hr)
HR (1) HRP20211336T1 (hr)
HU (1) HUE055473T2 (hr)
IL (1) IL252216B (hr)
MA (1) MA40933A (hr)
MX (1) MX2017006152A (hr)
PH (1) PH12017500854A1 (hr)
PL (1) PL3218358T3 (hr)
PT (1) PT3218358T (hr)
RS (1) RS62289B1 (hr)
RU (1) RU2712091C2 (hr)
SG (1) SG11201703579UA (hr)
SI (1) SI3218358T1 (hr)
WO (1) WO2016075130A1 (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
GB201514758D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
EP4086259A1 (en) 2015-11-06 2022-11-09 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
MA54567A (fr) * 2016-01-05 2021-10-27 Incyte Corp Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
US10993947B2 (en) 2016-05-18 2021-05-04 Torqur Treatment of skin lesions
RU2765868C2 (ru) * 2016-05-18 2022-02-04 Торкур АГ Лечение неврологических расстройств
AU2017265384B2 (en) * 2016-05-18 2023-02-23 The Trustees Of The University Of Pennsylvania Treatment of skin lesions
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
CN107266422A (zh) * 2017-06-12 2017-10-20 西安交通大学 2‑（5‑嘧啶基）‑4‑吗啉基‑6‑取代均三嗪类化合物及其盐、制备方法和应用
MX2020003862A (es) 2017-10-18 2020-08-13 Incyte Corp Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma).
CN109810100B (zh) * 2017-11-21 2022-03-11 中国药科大学 含有苯并呋喃的parp-1和pi3k双靶点抑制剂
RU2020115351A (ru) 2017-11-23 2021-12-23 Пикур Терапьютикс Аг Лечение кожных заболеваний
WO2020030708A1 (en) 2018-08-07 2020-02-13 Piqur Therapeutics Ag Treatment of squamous cell carcinoma
DK3847175T3 (da) 2018-09-05 2024-03-18 Incyte Corp Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor
CN113906026A (zh) * 2019-06-06 2022-01-07 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN111039874B (zh) * 2019-12-13 2022-11-04 南开大学 一种2-胺基-4-甲基嘧啶化合物的零废水制备方法
KR20210158019A (ko) 2020-06-23 2021-12-30 주식회사 온코빅스 포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물
WO2022214701A1 (en) * 2021-04-09 2022-10-13 Universität Basel Triazine derivative as covalent inhibitors of pi3k

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088112A1 (fr) * 2001-04-27 2002-11-07 Zenyaku Kogyo Kabushiki Kaisha Compose heterocyclique et agent antitumoral contenant ce dernier en tant qu'ingredient actif
AU2006221285B2 (en) * 2005-03-11 2011-03-31 Zenyaku Kogyo Kabushikikaisha Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EA200901065A1 (ru) * 2007-02-06 2010-02-26 Новартис Аг Ингибиторы pi 3-киназы и способы их применения
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
CN104245693B (zh) * 2012-12-14 2016-08-24 上海恒瑞医药有限公司 嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
PH12017500854A1 (en) 2017-11-06
SI3218358T1 (sl) 2021-10-29
KR20170101899A (ko) 2017-09-06
CA2965565C (en) 2023-09-19
CY1124444T1 (el) 2022-07-22
ES2886008T3 (es) 2021-12-16
RU2017111265A3 (hr) 2019-02-19
US20190031682A1 (en) 2019-01-31
BR112017009457A2 (pt) 2017-12-19
CN107108644A (zh) 2017-08-29
RU2712091C2 (ru) 2020-01-24
HUE055473T2 (hu) 2021-11-29
US20200277304A1 (en) 2020-09-03
JP2017533246A (ja) 2017-11-09
AU2015345233B2 (en) 2020-01-02
CA2965565A1 (en) 2016-05-19
MX2017006152A (es) 2017-07-19
US11186591B2 (en) 2021-11-30
AU2015345233A1 (en) 2017-05-25
RS62289B1 (sr) 2021-09-30
IL252216B (en) 2021-12-01
US10640516B2 (en) 2020-05-05
PT3218358T (pt) 2021-09-10
EP3218358B1 (en) 2021-06-16
PL3218358T3 (pl) 2022-03-14
DK3218358T3 (da) 2021-08-30
SG11201703579UA (en) 2017-05-30
MA40933A (fr) 2017-09-19
JP6689843B2 (ja) 2020-04-28
EP3218358A1 (en) 2017-09-20
CN107108644B (zh) 2021-01-05
NZ731504A (en) 2021-04-30
WO2016075130A1 (en) 2016-05-19
RU2017111265A (ru) 2018-12-14
IL252216A0 (en) 2017-07-31
BR112017009457A8 (pt) 2023-01-10
US20220153752A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
HRP20211336T1 (hr) Difluorometil-aminopiridini i difluorometil-aminopirimidini
ES2728163T3 (es) Compuestos de triazina como inhibidores de PI3 cinasa y mTOR
HRP20210477T1 (hr) Liječenje neuroloških poremećaja
IL279728B2 (en) Modified naphthyridinone compounds useful as t-cell activators
HRP20210431T1 (hr) Pripravci tetrahidrokinolina kao inhibitori bet bromodomene
HRP20171913T1 (hr) Aminopirimidinilni spojevi kao inhibitori jak
HRP20240547T1 (hr) Supstituirani triciklički spojevi
JP2019512482A5 (hr)
HRP20220468T1 (hr) Novi derivati izoksazolil etera kao gaba a alpha5 pam
HRP20100603T1 (hr) Derivati pirimidina koji se koriste kao inhibitori pi-3 kinaze
RU2014124640A (ru) Производные аминопиримидина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
HRP20140265T1 (hr) Derivat aminopirazina i odgovarajuä†i lijek
HRP20201331T1 (hr) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-oni i 1,5-dihidro-4h-pirazolo[3,4-c]pirimidin-4-oni kao inhibitori pde1
HRP20211957T1 (hr) Analozi 1,4-disupstituiranog piridazina i postupci za liječenje stanja povezanih s nedostatkom smn
RU2016137674A (ru) Производные пиперидиндиона
JP2016528298A5 (hr)
JP2016522231A5 (hr)
JP2012524103A5 (hr)
GB2609879A (en) Antagonists of the adenosine A2a receptor
RU2014109747A (ru) Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor
RU2018140001A (ru) Лечение повреждений кожи
IL295563A (en) Quinolyl phosphine oxide compound, and its assembly and application
IL274132B1 (en) Treatment of skin problems
US20170224696A9 (en) Triazine compounds as pi3 kinase and mtor inhibitors